KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Tax Provisions (2021 - 2025)

Rigel Pharmaceuticals has reported Tax Provisions over the past 3 years, most recently at -$245.4 million for Q4 2025.

  • Quarterly results put Tax Provisions at -$245.4 million for Q4 2025, down 27949.15% from a year ago — trailing twelve months through Dec 2025 was -$245.2 million (down 27927.7% YoY), and the annual figure for FY2025 was -$245.2 million, down 27931.67%.
  • Tax Provisions for Q4 2025 was -$245.4 million at Rigel Pharmaceuticals, down from -$280000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for RIGL hit a ceiling of $1.8 million in Q1 2021 and a floor of -$245.4 million in Q4 2025.
  • Median Tax Provisions over the past 3 years was -$65000.0 (2021), compared with a mean of -$27.1 million.
  • Peak annual rise in Tax Provisions hit 27949.15% in 2025, while the deepest fall reached 27949.15% in 2025.
  • Rigel Pharmaceuticals' Tax Provisions stood at -$65000.0 in 2021, then surged by 1455.38% to $881000.0 in 2024, then crashed by 27949.15% to -$245.4 million in 2025.
  • The last three reported values for Tax Provisions were -$245.4 million (Q4 2025), -$280000.0 (Q3 2025), and $369000.0 (Q2 2025) per Business Quant data.